-
Ciltacabtagene autoleucel, sold
under the
brand name Carvykti, is an anti-cancer
medication used to
treat multiple myeloma.
Ciltacabtagene autoleucel is a BCMA...
-
Brexucabtagene autoleucel, sold
under the
brand name Tecartus, is a cell-based gene
therapy medication for the
treatment of
mantle cell
lymphoma (MCL)...
-
Afamitresgene autoleucel, sold
under the
brand name
Tecelra is a T cell
immunotherapy used for the
treatment of
synovial sarcoma. It is a T cell receptor...
-
Obecabtagene autoleucel, sold
under the
brand name Aucatzyl, is an anti-cancer
medication used for the
treatment of
acute lymphoblastic leukemia. It is...
-
radiotherapy in this
disease is less
clear than for chemotherapy.
Afamitresgene autoleucel (Tecelra) was
approved for
medical use in the
United States in August...
-
autotemcel (Zynteglo):
treatment for beta thal****emia
Brexucabtagene autoleucel (Tecartus):
treatment for
mantle cell
lymphoma and
acute lymphoblastic...
- "TECARTUS (brexucabtagene
autoleucel)". FDA.
European Medicines Agency (2023-01-30). "TECARTUS (brexucabtagene
autoleucel)". EMA.
Center for Biologics...
-
ciloleucel L01XL04
Tisagenlecleucel L01XL05
Ciltacabtagene autoleucel L01XL06
Brexucabtagene autoleucel L01XL07
Idecabtagene vicleucel L01XL08 Lisocabtagene...
-
receptor into
their DNA, one that
recognizes leukemia cells.
Obecabtagene autoleucel (Aucatzyl) was
approved for
medical use in the
United States in November...
- the
cancerous cells and
there have been
several trials.
Afamitresgene autoleucel, sold
under the
brand name Tecelra, is an
autologous T cell immunotherapy...
